ORCID Profile
0000-0002-8450-6484
Current Organisations
Kent and Medway NHS and Social Care Partnership Trust
,
Kent and Medway Medical School
,
Royal College of Psychiatrists
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Related Links
Publications
E-Poster Presentations
Publisher: Royal College of Psychiatrists
Date: 07-2020
Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group tri
Publisher: Springer Science and Business Media LLC
Date: 06-01-2020
DOI: 10.1186/S13063-019-3758-9
Abstract: People experiencing their first episode of psychosis are often deficient in vitamin D. Observational studies have reported an association between low vitamin D concentrations and poorer subsequent health outcomes in psychosis. A vitamin D deficiency in neonates and children has been linked to a later increased risk of schizophrenia and psychotic-like experiences. This trial aims to examine the effect of high-dose vitamin D supplementation on outcomes in early psychosis. We hypothesise that vitamin D supplementation will be associated with better mental health outcomes. The DFEND study is a multicentre double-blind placebo-controlled parallel-group trial of vitamin D supplementation in people with early psychosis. Patients with an ICD-10 diagnosis of functional psychosis will be randomised in a 1:1 ratio to receive either 120,000 IU/month of vitamin D (cholecalciferol) or a matched placebo for 6 months. The primary outcome is the total Positive and Negative Syndrome Scale (PANSS) score at the 6-month follow-up for all patients. Secondary outcomes include assessment of mood (Calgary Depression Scale), general function (Global Assessment of Functioning), cardiovascular risk (body mass index, waist circumference, C-reactive protein, cholesterol and HbA1c) and vitamin D levels at the 6-month follow-up. Additionally, 3- and 6-month total PANSS scores will be analysed for those with inadequate vitamin D levels at the baseline. The DFEND study is the first trial to examine whether vitamin D supplementation in early psychosis is associated with better mental health outcomes. The findings of this study may help to resolve the clinical equipoise regarding the benefits and cost-effectiveness of routine vitamin D supplementation in people with psychosis. ISRCTN, ISRCTN12424842 . Registered on 25 February 2015.
Effect of Vitamin D Supplementation on Outcomes in People With Early Psychosis
Publisher: American Medical Association (AMA)
Date: 28-12-2021
Related Organisations
Kent And Medway NHS And Social Care Partnership Trust
Location: United Kingdom of Great Britain and Northern Ireland
South West London And St George's Mental Health NHS Trust
Location: United Kingdom of Great Britain and Northern Ireland
Kent And Medway Medical School
Location: United Kingdom of Great Britain and Northern Ireland
Acharya Shri Chander College Of Medical Sciences And Hospital
Location: India
Royal College Of Psychiatrists
Location: United Kingdom of Great Britain and Northern Ireland
South London And Maudsley NHS Foundation Trust
Location: United Kingdom of Great Britain and Northern Ireland
Northumbria University
Location: United Kingdom of Great Britain and Northern Ireland
Related Funding Activities
No related grants have been discovered for Muhammad Firdosi.